These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 32581056)

  • 21. Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC.
    Chen Y; Shao Z; Hao Z; Xin Z; Chen X; Huang L; Chen D; Lin M; Liu Q; Xu X; Li J; Wu D; Yan J; Chai Y; Wu P
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39134346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses.
    Wei J; Montalvo-Ortiz W; Yu L; Krasco A; Ebstein S; Cortez C; Lowy I; Murphy AJ; Sleeman MA; Skokos D
    Sci Immunol; 2021 Apr; 6(58):. PubMed ID: 33837124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens.
    Grimaldi A; Cammarata I; Martire C; Focaccetti C; Piconese S; Buccilli M; Mancone C; Buzzacchino F; Berrios JRG; D'Alessandris N; Tomao S; Giangaspero F; Paroli M; Caccavale R; Spinelli GP; Girelli G; Peruzzi G; Nisticò P; Spada S; Panetta M; Letizia Cecere F; Visca P; Facciolo F; Longo F; Barnaba V
    Commun Biol; 2020 Feb; 3(1):85. PubMed ID: 32099064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
    Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
    Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
    Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
    J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
    Zhang S; Bai X; Shan F
    Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tetrandrine activates STING/TBK1/IRF3 pathway to potentiate anti-PD-1 immunotherapy efficacy in non-small cell lung cancer.
    Tan Y; Zhu Q; Yang M; Yang F; Zeng Q; Jiang Z; Li D
    Pharmacol Res; 2024 Sep; 207():107314. PubMed ID: 39059614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combined model of serum neutrophil extracellular traps, CD8
    Guo J; Shu T; Zhang H; Huang N; Ren J; Lin L; Wu J; Wang Y; Huang Z; Bin J; Liao Y; Shi M; Liao W; Huang N
    FEBS J; 2024 Aug; 291(15):3403-3416. PubMed ID: 38661680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
    Zhang N; Gao Y; Zeng Z; Luo Y; Jiang X; Zhang J; Li J; Zhang J; Gong Y; Xie C
    Clin Transl Oncol; 2021 Sep; 23(9):1827-1837. PubMed ID: 33774805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8
    Liu Y; Zhang T; Zhang L; Zhao C; Zhang Z; Wang Z; Gu M; Li W; Li B
    Immunotherapy; 2022 Jun; 14(9):695-708. PubMed ID: 35574588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.
    Markowitz GJ; Havel LS; Crowley MJ; Ban Y; Lee SB; Thalappillil JS; Narula N; Bhinder B; Elemento O; Wong ST; Gao D; Altorki NK; Mittal V
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.
    Vashisht Gopal YN; Gammon S; Prasad R; Knighton B; Pisaneschi F; Roszik J; Feng N; Johnson S; Pramanik S; Sudderth J; Sui D; Hudgens C; Fischer GM; Deng W; Reuben A; Peng W; Wang J; McQuade JL; Tetzlaff MT; Di Francesco ME; Marszalek J; Piwnica-Worms D; DeBerardinis RJ; Davies MA
    Clin Cancer Res; 2019 Nov; 25(21):6429-6442. PubMed ID: 31439581
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.
    Peng DH; Rodriguez BL; Diao L; Gaudreau PO; Padhye A; Konen JM; Ochieng JK; Class CA; Fradette JJ; Gibson L; Chen L; Wang J; Byers LA; Gibbons DL
    Nat Commun; 2021 May; 12(1):2606. PubMed ID: 33972557
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-1 blockade combined with IL-33 enhances the antitumor immune response in a type-1 lymphocyte-mediated manner.
    He H; Shi L; Meng D; Zhou H; Ma J; Wu Y; Wu Y; Gu Y; Xie W; Zhang J; Zhu Y
    Cancer Treat Res Commun; 2021; 28():100379. PubMed ID: 33951555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CDK7 inhibitor THZ1 enhances antiPD-1 therapy efficacy via the p38α/MYC/PD-L1 signaling in non-small cell lung cancer.
    Wang J; Zhang R; Lin Z; Zhang S; Chen Y; Tang J; Hong J; Zhou X; Zong Y; Xu Y; Meng R; Xu S; Liu L; Zhang T; Yang K; Dong X; Wu G
    J Hematol Oncol; 2020 Jul; 13(1):99. PubMed ID: 32690037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
    Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
    Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.